MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
31.41
-1.44
-4.38%
After Hours: 31.21 -0.2 -0.64% 19:30 09/25 EDT
OPEN
33.12
PREV CLOSE
32.85
HIGH
33.40
LOW
30.75
VOLUME
232.44K
TURNOVER
--
52 WEEK HIGH
45.50
52 WEEK LOW
4.971
MARKET CAP
228.18M
P/E (TTM)
-1.1637
1D
5D
1M
3M
1Y
5Y
1D
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
Seeking Alpha · 5d ago
B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff
TipRanks · 5d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 5d ago
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset
Seeking Alpha · 5d ago
What's Going on With Cue Biopharma Stock on Monday?
Benzinga · 5d ago
Cue Biopharma reports positive Phase 2 CUE-221 data
TipRanks · 5d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 5d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 5d ago
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.